Annual revenue went from KRW 150 million in 2022 to KRW 91.52 million in 2023, down 39.1%, then rose to KRW 1.07 billion in 2024, up 1,071.5%, making 2024 the largest year of the 2022 to 2025 window.
Revenue fell 65.4% to KRW 370 million in 2025, far below the KRW 3.7 billion that the IPO registration statement had projected for that year. Operating loss narrowed from KRW 10 billion in 2022 to KRW 6.81 billion in 2023, then widened to KRW 6.96 billion in 2024 and KRW 8.83 billion in 2025.
The operating margin improved in 2024 to -649.6%, mainly because the revenue base was larger, while the absolute operating loss stayed close to the 2023 level. The margin deteriorated again to -2,383.0% in 2025 as revenue shrank and costs rose.
The company attributed the 2025 decline to fewer new drug evaluation service orders and higher costs for developing multi-omics analysis technology to upgrade its AI platform.
Net loss attributable to controlling shareholders widened from KRW 4.21 billion in 2023 to KRW 6.48 billion in 2024 and KRW 8.93 billion in 2025, and the total net loss reported each year matches these figures.
The debt-to-equity ratio rose from 6.7% in 2023 to 116.5% in 2025, which appears to coincide with the KRW 12.5 billion convertible bond issued in July 2025. Operating cash flow was negative in every year, at -KRW 8.2 billion in 2022, -KRW 4.91 billion in 2023, -KRW 5.52 billion in 2024 and -KRW 7.41 billion in 2025.
Quarterly revenue was KRW 29.18 million in Q3 2025, KRW 141 million in Q4 2025, KRW 167 million in Q1 2026, KRW 58.12 million in Q2 2026 and KRW 90.12 million in Q3 2026, a volatile path. Q3 2026 revenue rose 208.8% from the year-earlier quarter, yet operating loss widened to KRW 2.87 billion in the same quarter.
In Q2 2026, net profit attributable to controlling shareholders was KRW 1.01 billion despite an operating loss of KRW 2.7 billion, a gap that appears to reflect non-operating items, and the breakdown should be checked in the annual report.